DOCSLIB.ORG

Cannabinoids Delivery Systems Based on Supramolecular Inclusion Complexes and Polymeric Nanocapsules for Treatment of Neuropathic Pain Fanny Astruc-Diaz

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cannabinoids Delivery Systems Based on Supramolecular Inclusion Complexes and Polymeric Nanocapsules for Treatment of Neuropathic Pain Fanny Astruc-Diaz Cannabinoids delivery systems based on supramolecular inclusion complexes and polymeric nanocapsules for treatment of neuropathic pain Fanny Astruc-Diaz To cite this version: Fanny Astruc-Diaz. Cannabinoids delivery systems based on supramolecular inclusion complexes and polymeric nanocapsules for treatment of neuropathic pain. Human health and pathology. Université Claude Bernard - Lyon I, 2012. English. NNT : 2012LYO10099. tel-00935588 HAL Id: tel-00935588 https://tel.archives-ouvertes.fr/tel-00935588 Submitted on 23 Jan 2014 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. N° d’ordre : 99-2012 Année 2012 THESE DE L‘UNIVERSITE DE LYON Délivrée par L’UNIVERSITE CLAUDE BERNARD LYON 1 ECOLE DOCTORALE DE CHIMIE DIPLOME DE DOCTORAT (arrêté du 7 août 2006) soutenue publiquement le 9 Juillet 2012 par Mme. ASTRUC-DIAZ Fanny CANNABINOIDS DELIVERY SYSTEMS BASED ON SUPRAMOLECULAR INCLUSION COMPLEXES AND POLYMERIC NANOCAPSULES FOR TREATMENT OF NEUROPATHIC PAIN Jury Mme. DUCKI Sylvie Rapporteur M. VIERLING Pierre Rapporteur M. DUTASTA Jean-Pierre Examinateur M. PAROLA Stéphane Directeur de thèse M. THOMPSON Charles Examinateur - 1 - | Page gÉ `tààxÉ tÇw `tå|Åx? gÉ c{|Ä|ÑÑx? - 2 - | Page ACKNOWLEGEMENTS I would like to give my sincere gratitude to my advisor, Dr. Stephane Parola, for his confidence and for giving me the opportunity of conducting this Ph.D research. I wish to give my profoundness appreciation to Dr. Philippe Diaz for his excellence guidance, patience, caring and time to complete this work. I would like to thank Dr. Charles Thompson for generously giving me the time and the support to achieve this project. I would also like to thank my Jury members for their time to review my dissertation. I am appreciative of the help I've received from my colleagues at the University of Montana, Steven McDaniel for the cyclodextrin molecular modeling, Dr. James Driver for conducting the nanocapsules morphological studies, Dr. Christopher Palmer for his guidance with the use of the GC-MS, Dr. Ravil Petrov for his help and practical experience in the laboratory, and Dr. Nicolas Guilloteau and Dr. Yamina Belabassi for their warm words of encouragement. I am also appreciative for my co-workers at MD Anderson Cancer Center and Dr. Mohamed Naguib for giving me the opportunity to work in his laboratory, Dr. Gabriel Lopez-Berestein for teaching me how to make non ionic liposomes and Dr. Pablo Vivas-Mejia for his help preparing them. I would like to give my gratitude to Dr. Jon Nagy and Ryan Holly for hosting me in their laboratory and assisting me with particle sizing studies. Finally, I would like to thank my friend, Agnes, and my family, my mum and my sister Melanie for their unconditional trust and support through all this difficult and rewarding experience, and my dad who passed away before the completion of this thesis. I am gratefuI to my parents in law, Nelly and Mario for their gentleness and their help taking care of my sons while I was busy preparing my seminar. I would also like to thank my sons for their love and patience even when I was frustrated and not available for them. Most of all, I would like to thank my husband who loved me when I deserved it the least but when I needed the most. - 3 - | Page TABLE OF CONTENTS LIST OF ABBREVIATIONS.……………….………………………………………..- 10 - INTRODUCTION AND OBJECTIVES.…………………………………………...- 15 - CHAPTER I: BIBLIOGRAPHY.………………………………………..……….......- 17 - 1. Cannabis. .......................................................................................................... - 17 - 2. Endocannabinoid system. .................................................................................. - 18 - 3. Cannabinoid receptors. ..................................................................................... - 20 - 4. Endocannabinoids.............................................................................................. - 21 - 5. Enzymes. ........................................................................................................... - 23 - 6. Cannabinoid receptor-mediated intracellular signal pathways. .......................... - 26 - 7. Interactions of cannabinoids with some other receptor systems. ....................... - 28 - 8. Drug of abuse..................................................................................................... - 30 - 9. Therapeutic cannabinoid derivatives on the market. .......................................... - 31 - 10. Phytocannabinoids. ............................................................................................ - 32 - 11. Pain. ................................................................................................................... - 34 - 11.1. Physiological pain............................................................................................ - 34 - 11.2. Neuropathic pain. ............................................................................................ - 37 - 12. CB2 receptors: a target for Neuropathic Pain treatment? .................................. - 42 - 13 References. ........................................................................................................ - 44 - CHAPTER II EARLY FORMULATION AND ENABLING DRUG DELIVERY SYSTEMS DESIGN.............................................................................................. - 62 - 1 Introduction. ................................................................................................ ……- 62 - 1.2 Cyclodextrins. .................................................................................................. - 65 - 1.2.1 Cyclodextrins and complexation. ............................................................................... - 67 - 1.3 Liposomes. ...................................................................................................... - 78 - 1.4 Micelles. .......................................................................................................... - 82 - - 4 - | Page 1.5 Oral Self-Emulsifying Drug Delivery System (SEDDS). ……………………….- 87 - 2 Development of enabling Drug Delivery Systems for the in vivo administration of a series of lipophilic synthetic cannabinoids. ......................................................... - 89 - 2.1 MDA7. ............................................................................................................. - 91 - 2.2 MDA7 physico-chemical properties. ................................................................ - 91 - 2.3 In vitro characterization of MDA7. ................................................................... - 92 - 2.4 Enabling Drug Delivery System design and development. .............................. - 94 - 2.4.1 Preformulation studies. .............................................................................................. - 95 - 2.4.2 MDA7 enabling DDS design and development. ................................................... - 97 - 2.5 In vivo characterization of MDA7. .................................................................. - 130 - 2.5.1 Pharmacokinetic study. ................................................................................... - 130 - 2.5.2 Influence of the DDS selected on MDA7 in vivo efficacy. .................................... - 132 - 2.5.3 Effect of MDA7 administered intraperitoneally on models of nociception in rats. ….- 135 - 2.5.4 Effects of MDA7 on tactile allodynia in the spinal nerve ligation model of neuropathic pain. ……………………………………………………………………………………….- 136 - 2.5.5 Effects of MDA7 on tactile allodynia in a paclitaxel-induced neuropathic pain model. …………………………………………………………………………………………… - 139 - 2.5.6 Open-field chamber testing...................................................................................... - 140 - 2.6 Other cannabinoids evaluated in vivo............................................................ - 141 - 3 Summary and Conclusion. ............................................................................... - 144 - 4 References. ...................................................................................................... - 146 - CHAPTER III CATIONIC POLYMERIC NANOCAPSULES.…......………- 159 - 1 Review. ............................................................................................................ - 159 - 1.1 Structure of drug-loaded nanoparticles. ........................................................ - 159 - 2 Applications of drug-loaded polymeric nanoparticles. ...................................... - 160 - 3 Nanoparticles uptake in cells............................................................................ - 161 - 4 Drug-loaded nanoparticles composition and bioadhesion. ............................... - 161 - 5 Methods of preparation of polymeric drug-loaded nanoparticles. ..................... - 162 - 6 Nanoprecipitation of preformed polymer. ......................................................... - 163 - - 5 - | Page 7 Nanoparticles and oral delivery. ....................................................................... - 164 - 8 Concepts
Load more

Recommended publications
  • Download Product Insert (PDF)
    PRODUCT INFORMATION Hemopressin Item No. 10011038 Contents: This vial contains 1 mg peptide Peptide Sequence: Rat hemopressin PVNFKFLSH Mr: 1,088 Da Stability: ≥1 year at -20°C Supplied as: 1 mg peptide Solubility: Sparingly soluble (0.05 mg/ml) with sterile filtered water Laboratory Procedures This peptide is sparingly soluble in water and the following resuspension technique is recommended. Bring the peptide to room temperature and empty the contents of the vial into a 25 ml graduated cylinder. Use 1 ml serial aliquots of sterile filtered water to dissolve any remaining peptide in the glass vial to quantitatively transfer the total amount to the cylinder. Finally, add sterile filtered water to 20 ml final volume and mix gently to dissolve fully. One milligram of hemopressin dissolved in 20 ml water provides a 45.9 µM solution. One milligram per milliliter concentrations of hemopressin may also be prepared with the use of 10% methanol in water containing 0.1% trifluoroacetic acid. Description Rat hemopressin is a bioactive peptide fragment derived from the hemoglobin α1 chain. Hemopressin exhibits potent vasoactive biological activity, reducing rat blood pressure over a dosage range of 1 0.1-10 μg/kg. This peptide is also a potent central cannabinoid (CB1) receptor antagonist conferring analgesia and pain relief or antinociception in vivo.2 Further studies will clarify the cellular and physiological effects of hemopressin, as well the possible products of endopeptidase activity on hemopressin.1,2 References 1. Rioli, V., Gozzo, F.C., Heimann, A.S., et al. Novel natural peptide substrates for endopeptidase 24.15, neurolysin, and angiotensin-converting enzyme.
    [Show full text]
  • Edinburgh Research Explorer
    Edinburgh Research Explorer International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list Citation for published version: Davenport, AP, Alexander, SPH, Sharman, JL, Pawson, AJ, Benson, HE, Monaghan, AE, Liew, WC, Mpamhanga, CP, Bonner, TI, Neubig, RR, Pin, JP, Spedding, M & Harmar, AJ 2013, 'International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands', Pharmacological reviews, vol. 65, no. 3, pp. 967-86. https://doi.org/10.1124/pr.112.007179 Digital Object Identifier (DOI): 10.1124/pr.112.007179 Link: Link to publication record in Edinburgh Research Explorer Document Version: Publisher's PDF, also known as Version of record Published In: Pharmacological reviews Publisher Rights Statement: U.S. Government work not protected by U.S. copyright General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 02. Oct. 2021 1521-0081/65/3/967–986$25.00 http://dx.doi.org/10.1124/pr.112.007179 PHARMACOLOGICAL REVIEWS Pharmacol Rev 65:967–986, July 2013 U.S.
    [Show full text]
  • Handbook of Herbs and Spices
    Handbook of herbs and spices Edited by K. V. Peter Published by Woodhead Publishing Limited Abington Hall, Abington Cambridge CB1 6AH England www.woodhead-publishing.com Published in North and South America by CRC Press LLC 2000 Corporate Blvd, NW Boca Raton FL 33431 USA First published 2001, Woodhead Publishing Limited and CRC Press LLC ß 2001, Woodhead Publishing Limited The authors have asserted their moral rights. This book contains information obtained from authentic and highly regarded sources. Reprinted material is quoted with permission, and sources are indicated. Reasonable efforts have been made to publish reliable data and information, but the authors and the publishers cannot assume responsibility for the validity of all materials. Neither the authors nor the publishers, nor anyone else associated with this publication, shall be liable for any loss, damage or liability directly or indirectly caused or alleged to be caused by this book. Neither this book nor any part may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, microfilming, and recording, or by any information storage or retrieval system, without prior permission in writing from the publishers. The consent of Woodhead Publishing Limited and CRC Press LLC does not extend to copying for general distribution, for promotion, for creating new works, or for resale. Specific permission must be obtained in writing from Woodhead Publishing Limited or CRC Press LLC for such copying. Trademark notice: Product or corporate names may be trademarks or registered trademarks, and are used only for identification and explanation, without intent to infringe. British Library Cataloguing in Publication Data A catalogue record for this book is available from the British Library.
    [Show full text]
  • N-Acyl-Dopamines: Novel Synthetic CB1 Cannabinoid-Receptor Ligands
    Biochem. J. (2000) 351, 817–824 (Printed in Great Britain) 817 N-acyl-dopamines: novel synthetic CB1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo Tiziana BISOGNO*, Dominique MELCK*, Mikhail Yu. BOBROV†, Natalia M. GRETSKAYA†, Vladimir V. BEZUGLOV†, Luciano DE PETROCELLIS‡ and Vincenzo DI MARZO*1 *Istituto per la Chimica di Molecole di Interesse Biologico, C.N.R., Via Toiano 6, 80072 Arco Felice, Napoli, Italy, †Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, R. A. S., 16/10 Miklukho-Maklaya Str., 117871 Moscow GSP7, Russia, and ‡Istituto di Cibernetica, C.N.R., Via Toiano 6, 80072 Arco Felice, Napoli, Italy We reported previously that synthetic amides of polyunsaturated selectivity for the anandamide transporter over FAAH. AA-DA fatty acids with bioactive amines can result in substances that (0.1–10 µM) did not displace D1 and D2 dopamine-receptor interact with proteins of the endogenous cannabinoid system high-affinity ligands from rat brain membranes, thus suggesting (ECS). Here we synthesized a series of N-acyl-dopamines that this compound has little affinity for these receptors. AA-DA (NADAs) and studied their effects on the anandamide membrane was more potent and efficacious than anandamide as a CB" transporter, the anandamide amidohydrolase (fatty acid amide agonist, as assessed by measuring the stimulatory effect on intra- hydrolase, FAAH) and the two cannabinoid receptor subtypes, cellular Ca#+ mobilization in undifferentiated N18TG2 neuro- CB" and CB#. NADAs competitively inhibited FAAH from blastoma cells. This effect of AA-DA was counteracted by the l µ N18TG2 cells (IC&! 19–100 M), as well as the binding of the CB" antagonist SR141716A.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • 2-Arachidonoylglycerol a Signaling Lipid with Manifold Actions in the Brain
    Progress in Lipid Research 71 (2018) 1–17 Contents lists available at ScienceDirect Progress in Lipid Research journal homepage: www.elsevier.com/locate/plipres Review 2-Arachidonoylglycerol: A signaling lipid with manifold actions in the brain T ⁎ Marc P. Baggelaara,1, Mauro Maccarroneb,c,2, Mario van der Stelta, ,2 a Department of Molecular Physiology, Leiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2333 CC Leiden, The Netherlands. b Department of Medicine, Campus Bio-Medico University of Rome, Via Alvaro del Portillo 21, 00128 Rome, Italy c European Centre for Brain Research/IRCCS Santa Lucia Foundation, via del Fosso del Fiorano 65, 00143 Rome, Italy ABSTRACT 2-Arachidonoylglycerol (2-AG) is a signaling lipid in the central nervous system that is a key regulator of neurotransmitter release. 2-AG is an endocannabinoid that activates the cannabinoid CB1 receptor. It is involved in a wide array of (patho)physiological functions, such as emotion, cognition, energy balance, pain sensation and neuroinflammation. In this review, we describe the biosynthetic and metabolic pathways of 2-AG and how chemical and genetic perturbation of these pathways has led to insight in the biological role of this signaling lipid. Finally, we discuss the potential therapeutic benefits of modulating 2-AG levels in the brain. 1. Introduction [24–26], locomotor activity [27,28], learning and memory [29,30], epileptogenesis [31], neuroprotection [32], pain sensation [33], mood 2-Arachidonoylglycerol (2-AG) is one of the most extensively stu- [34,35], stress and anxiety [36], addiction [37], and reward [38]. CB1 died monoacylglycerols. It acts as an important signal and as an in- receptor signaling is tightly regulated by biosynthetic and catabolic termediate in lipid metabolism [1,2].
    [Show full text]
  • The Selective Reversible FAAH Inhibitor, SSR411298, Restores The
    www.nature.com/scientificreports OPEN The selective reversible FAAH inhibitor, SSR411298, restores the development of maladaptive Received: 22 September 2017 Accepted: 26 January 2018 behaviors to acute and chronic Published: xx xx xxxx stress in rodents Guy Griebel1, Jeanne Stemmelin2, Mati Lopez-Grancha3, Valérie Fauchey3, Franck Slowinski4, Philippe Pichat5, Gihad Dargazanli4, Ahmed Abouabdellah4, Caroline Cohen6 & Olivier E. Bergis7 Enhancing endogenous cannabinoid (eCB) signaling has been considered as a potential strategy for the treatment of stress-related conditions. Fatty acid amide hydrolase (FAAH) represents the primary degradation enzyme of the eCB anandamide (AEA), oleoylethanolamide (OEA) and palmitoylethanolamide (PEA). This study describes a potent reversible FAAH inhibitor, SSR411298. The drug acts as a selective inhibitor of FAAH, which potently increases hippocampal levels of AEA, OEA and PEA in mice. Despite elevating eCB levels, SSR411298 did not mimic the interoceptive state or produce the behavioral side-efects (memory defcit and motor impairment) evoked by direct-acting cannabinoids. When SSR411298 was tested in models of anxiety, it only exerted clear anxiolytic-like efects under highly aversive conditions following exposure to a traumatic event, such as in the mouse defense test battery and social defeat procedure. Results from experiments in models of depression showed that SSR411298 produced robust antidepressant-like activity in the rat forced-swimming test and in the mouse chronic mild stress model, restoring notably the development of inadequate coping responses to chronic stress. This preclinical profle positions SSR411298 as a promising drug candidate to treat diseases such as post-traumatic stress disorder, which involves the development of maladaptive behaviors. Te endocannabinoid (eCB) system is formed by two G protein-coupled receptors, CB1 and CB2, and their main transmitters, N-arachidonoylethanolamine (anandamide; AEA) and 2-arachidonoyglycerol (2-AG)1.
    [Show full text]
  • Identification of Biomarkers for Sarcoidosis and Tuberculosis of The
    DATABASE ANALYSIS e-ISSN 1643-3750 © Med Sci Monit, 2020; 26: e925438 DOI: 10.12659/MSM.925438 Received: 2020.04.26 Accepted: 2020.05.11 Identification of Biomarkers for Sarcoidosis and Available online: 2020.05.28 Published: 2020.07.23 Tuberculosis of the Lung Using Systematic and Integrated Analysis Authors’ Contribution: ABCEF 1 Min Zhao 1 Department of Respiratory and Critical Care Medicine, The Second Hospital of Study Design A BCE 1 Xin Di Jilin University, Changchun, Jilin, P.R. China Data Collection B 2 Department of Oncology and Hematology, The Second Hospital of Jilin University, Statistical Analysis C CDE 2 Xin Jin Changchun, Jilin, P.R. China Data Interpretation D BF 1 Chang Tian Manuscript Preparation E CF 1 Shan Cong Literature Search F Funds Collection G BF 1 Jiangyin Liu ABDEG 1 Ke Wang Corresponding Author: Ke Wang, e-mail: [email protected] Source of support: This study was supported by the Technology Research Funds of Jilin Province (20190303162SF), the Natural Science Foundation of Jilin Province (20180101103JC), and the Medical and Health Project Funds of Jilin Province (20191102012YY) Background: Sarcoidosis (SARC) is a multisystem inflammatory disease of unknown etiology and pulmonary tuberculosis (PTB) is caused by Mycobacterium tuberculosis. Both of these diseases affect lungs and lymph nodes and share similar clinical manifestations. However, the underlying mechanisms for the similarities and differences in ge- netic characteristics of SARC and PTB remain unclear. Material/Methods: Three datasets (GSE16538, GSE20050, and GSE19314) were retrieved from the Gene Expression Omnibus (GEO) database. Differentially expressed genes (DEGs) in SARC and PTB were identified using GEO2R online analyz- er and Venn diagram software.
    [Show full text]
  • Trick Or Treat from Food Endocannabinoids?
    scientific correspondence 3. Casselman, J. M. in Proc. 1980 North Am. Eel Conf. (ed. Loftus, NAEs (0.01–5.8 mg per g) and oleamide of magnitude below those required, if K. H.) 74–82 (Ontario Ministry of Natural Resources, Ontario, (0.17–6.0 g per g), but no or very little administered by mouth, to reach the blood 1982). m 4. Radtke, R. L. Comp. Biochem. Physiol. A 92, 189–193 (1989). anandamide and no 2-AG. NAE levels are and cause observable ‘central’ effects. The 5. Kalish, J. M. J. Exp. Mar. Biol. Ecol. 132, 151–178 (1989). much lower in unfermented cocoa beans assays used here provide a gross evaluation of 6. Secor, D. H. Fish. Bull. US 90, 798–806 (1992). than in cocoa powder (which contained less cannabimimetic activity, and tests 7. Tzeng, W. N., Severin, K. P. & Wickström, H. Mar. Ecol. Prog. Ser. 149, 73–81 (1997). than 0.003 mg per g anandamide). Tiny monitoring more subtle behavioural changes 8. Angino, E. E., Billings, G. K. & Anderson, N. Chem. Geol. 1, amounts of anandamide in cocoa could that might be induced by low oral doses of 145–153 (1966). therefore be explained as artefacts of pro- NAEs/oleamide are needed before the rele- 9. Nakai, I., Iwata, R. & Tsukamoto, K. Spectrochim. Acta B (in the 2 cessing . Like all higher plants, cocoa plants vance of these compounds to the purported press). 8 10. Otake, T., Ishii, T., Nakahara, M. & Nakamura, R. Mar. Ecol. cannot synthesize arachidonic acid or its mild rewarding and craving-inducing effects 7 Prog.
    [Show full text]
  • Potential Cannabis Antagonists for Marijuana Intoxication
    Central Journal of Pharmacology & Clinical Toxicology Bringing Excellence in Open Access Review Article *Corresponding author Matthew Kagan, M.D., Cedars-Sinai Medical Center, 8730 Alden Drive, Los Angeles, CA 90048, USA, Tel: 310- Potential Cannabis Antagonists 423-3465; Fax: 310.423.8397; Email: Matthew.Kagan@ cshs.org Submitted: 11 October 2018 for Marijuana Intoxication Accepted: 23 October 2018 William W. Ishak, Jonathan Dang, Steven Clevenger, Shaina Published: 25 October 2018 Ganjian, Samantha Cohen, and Matthew Kagan* ISSN: 2333-7079 Cedars-Sinai Medical Center, USA Copyright © 2018 Kagan et al. Abstract OPEN ACCESS Keywords Cannabis use is on the rise leading to the need to address the medical, psychosocial, • Cannabis and economic effects of cannabis intoxication. While effective agents have not yet been • Cannabinoids implemented for the treatment of acute marijuana intoxication, a number of compounds • Antagonist continue to hold promise for treatment of cannabinoid intoxication. Potential therapeutic • Marijuana agents are reviewed with advantages and side effects. Three agents appear to merit • Intoxication further inquiry; most notably Cannabidiol with some evidence of antipsychotic activity • THC and in addition Virodhamine and Tetrahydrocannabivarin with a similar mixed receptor profile. Given the results of this research, continued development of agents acting on cannabinoid receptors with and without peripheral selectivity may lead to an effective treatment for acute cannabinoid intoxication. Much work still remains to develop strategies that will interrupt and reverse the effects of acute marijuana intoxication. ABBREVIATIONS Therapeutic uses of cannabis include chronic pain, loss of appetite, spasticity, and chemotherapy-associated nausea and CBD: Cannabidiol; CBG: Cannabigerol; THCV: vomiting [8]. Recreational cannabis use is on the rise with more Tetrahydrocannabivarin; THC: Tetrahydrocannabinol states approving its use and it is viewed as no different from INTRODUCTION recreational use of alcohol or tobacco [9].
    [Show full text]
  • The Expanded Endocannabinoid System/Endocannabinoidome As a Potential Target for Treating Diabetes Mellitus
    Current Diabetes Reports (2019) 19:117 https://doi.org/10.1007/s11892-019-1248-9 OBESITY (KM GADDE, SECTION EDITOR) The Expanded Endocannabinoid System/Endocannabinoidome as a Potential Target for Treating Diabetes Mellitus Alain Veilleux1,2,3 & Vincenzo Di Marzo1,2,3,4,5 & Cristoforo Silvestri3,4,5 # Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract Purpose of Review The endocannabinoid (eCB) system, i.e. the receptors that respond to the psychoactive component of cannabis, their endogenous ligands and the ligand metabolic enzymes, is part of a larger family of lipid signals termed the endocannabinoidome (eCBome). We summarize recent discoveries of the roles that the eCBome plays within peripheral tissues in diabetes, and how it is being targeted, in an effort to develop novel therapeutics for the treatment of this increasingly prevalent disease. Recent Findings As with the eCB system, many eCBome members regulate several physiological processes, including energy intake and storage, glucose and lipid metabolism and pancreatic health, which contribute to the development of type 2 diabetes (T2D). Preclinical studies increasingly support the notion that targeting the eCBome may beneficially affect T2D. Summary The eCBome is implicated in T2D at several levels and in a variety of tissues, making this complex lipid signaling system a potential source of many potential therapeutics for the treatments for T2D. Keywords Endocannabinoidome . Bioactive lipids . Peripheral tissues . Glucose . Insulin Introduction: The Endocannabinoid System cannabis-derived natural product, Δ9-tetrahydrocannabinol and its Subsequent Expansion (THC), responsible for most of the psychotropic, euphoric to the “Endocannabinoidome” and appetite-stimulating actions (via CB1 receptors) and immune-modulatory effects (via CB2 receptors) of marijuana, The discovery of two G protein-coupled receptors, the canna- opened the way to the identification of the endocannabinoids binoid receptor type-1 (CB1) and − 2 (CB2) [1, 2], for the (eCBs).
    [Show full text]
  • Harnessing the Endocannabinoid 2-Arachidonoylglycerol to Lower Intraocular Pressure in a Murine Model
    Glaucoma Harnessing the Endocannabinoid 2-Arachidonoylglycerol to Lower Intraocular Pressure in a Murine Model Sally Miller,1 Emma Leishman,1 Sherry Shujung Hu,2 Alhasan Elghouche,1 Laura Daily,1 Natalia Murataeva,1 Heather Bradshaw,1 and Alex Straiker1 1Department of Psychological and Brain Sciences, Indiana University, Bloomington, Indiana, United States 2Department of Psychology, National Cheng Kung University, Tainan, Taiwan Correspondence: Alex Straiker, De- PURPOSE. Cannabinoids, such as D9-THC, act through an endogenous signaling system in the partment of Psychological and Brain vertebrate eye that reduces IOP via CB1 receptors. Endogenous cannabinoid (eCB) ligand, 2- Sciences, Indiana University, Bloom- arachidonoyl glycerol (2-AG), likewise activates CB1 and is metabolized by monoacylglycerol ington, IN 47405, USA; lipase (MAGL). We investigated ocular 2-AG and its regulation by MAGL and the therapeutic [email protected]. potential of harnessing eCBs to lower IOP. Submitted: February 16, 2016 Accepted: May 16, 2016 METHODS. We tested the effect of topical application of 2-AG and MAGL blockers in normotensive mice and examined changes in eCB-related lipid species in the eyes and spinal Citation: Miller S, Leishman E, Hu SS, cord of MAGL knockout (MAGLÀ/À) mice using high performance liquid chromatography/ et al. Harnessing the endocannabinoid tandem mass spectrometry (HPLC/MS/MS). We also examined the protein distribution of 2-arachidonoylglycerol to lower intra- ocular pressure in a murine model. MAGL in the mouse anterior chamber. Invest Ophthalmol Vis Sci. RESULTS. 2-Arachidonoyl glycerol reliably lowered IOP in a CB1- and concentration-dependent 2016;57:3287–3296. DOI:10.1167/ manner. Monoacylglycerol lipase is expressed prominently in nonpigmented ciliary iovs.16-19356 epithelium.
    [Show full text]